A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs VT 1161 (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 11 Aug 2017 Results published in a Viamet Pharmaceuticals Media Release.
    • 11 Aug 2017 According to a Viamet Pharmaceuticals media release, data from this study were presented at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting.
    • 08 Aug 2017 According to a Viamet Pharmaceuticals media release, data from this study will be presented at the upcoming Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top